Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neutrophil elastase as a versatile cleavage enzyme for activation of αvβ3 integrin-targeted small molecule drug conjugates with different payload classes in the tumor microenvironment.
Rebstock AS, Wiedmann M, Stelte-Ludwig B, Wong H, Johnson AJ, Izumi R, Hamdy A, Lerchen HG. Rebstock AS, et al. Among authors: lerchen hg. Front Pharmacol. 2024 Mar 1;15:1358393. doi: 10.3389/fphar.2024.1358393. eCollection 2024. Front Pharmacol. 2024. PMID: 38495100 Free PMC article.
Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class.
Lerchen HG, Wittrock S, Stelte-Ludwig B, Sommer A, Berndt S, Griebenow N, Rebstock AS, Johannes S, Cancho-Grande Y, Mahlert C, Greven S, Terjung C. Lerchen HG, et al. Angew Chem Int Ed Engl. 2018 Nov 12;57(46):15243-15247. doi: 10.1002/anie.201807619. Epub 2018 Oct 15. Angew Chem Int Ed Engl. 2018. PMID: 30180286
Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.
Sommer A, Kopitz C, Schatz CA, Nising CF, Mahlert C, Lerchen HG, Stelte-Ludwig B, Hammer S, Greven S, Schuhmacher J, Braun M, Zierz R, Wittemer-Rump S, Harrenga A, Dittmer F, Reetz F, Apeler H, Jautelat R, Huynh H, Ziegelbauer K, Kreft B. Sommer A, et al. Among authors: lerchen hg. Cancer Res. 2016 Nov 1;76(21):6331-6339. doi: 10.1158/0008-5472.CAN-16-0180. Epub 2016 Aug 19. Cancer Res. 2016. PMID: 27543601
IL3RA-Targeting Antibody-Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic Malignancies.
Kirchhoff D, Stelte-Ludwig B, Lerchen HG, Wengner AM, Ahsen OV, Buchmann P, Märsch S, Mahlert C, Greven S, Dietz L, Erkelenz M, Zierz R, Johanssen S, Mumberg D, Sommer A. Kirchhoff D, et al. Among authors: lerchen hg. Cancers (Basel). 2020 Nov 20;12(11):3464. doi: 10.3390/cancers12113464. Cancers (Basel). 2020. PMID: 33233768 Free PMC article.
Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.
Willuda J, Linden L, Lerchen HG, Kopitz C, Stelte-Ludwig B, Pena C, Lange C, Golfier S, Kneip C, Carrigan PE, Mclean K, Schuhmacher J, von Ahsen O, Müller J, Dittmer F, Beier R, El Sheikh S, Tebbe J, Leder G, Apeler H, Jautelat R, Ziegelbauer K, Kreft B. Willuda J, et al. Among authors: lerchen hg. Mol Cancer Ther. 2017 May;16(5):893-904. doi: 10.1158/1535-7163.MCT-16-0474. Epub 2017 Mar 14. Mol Cancer Ther. 2017. PMID: 28292941
19 results